News and Insights
From Breakthrough to Scale: BIOAsia 2026 and Turning Science into Health Impact
February 19, 2026
There are moments at global convenings when the future shifts in real time.
At BIOAsia 2026 in Hyderabad, that shift was unmistakable. What was once a conversation about breakthrough science has matured into a disciplined dialogue about scale, access and execution. The question is no longer whether next-generation biologics will transform medicine. The question is whether we, as a global ecosystem, have the coordination and capability to deliver them to millions.
BIOAsia has become one of the world’s most influential life sciences gatherings, convening leaders from biotechnology, pharmaceuticals, health technology, venture capital, academia, and government. Hyderabad stands as a living case study in collaborative ambition aligned with infrastructure. The region’s expanding Global Capability Centers are not back offices. They are innovation engines supporting research, analytics, manufacturing excellence, and digital transformation for multinational enterprises.
This year, SPAG FINN Partners and FINN Partners were recognized by PRovoke Media as among the Top 30 Global Healthcare PR Agencies. The distinction reflects more than communications excellence. It signals trusted counsel at the intersection of science, policy, reputation and global growth. At BIOAsia, that trust translated into substantive engagement with multinational biopharmaceutical leaders, Indian innovators, regulators, and senior government officials shaping the next chapter of life sciences.
Throughout the week, SPAG/FINN colleagues demonstrated why local insight and disciplined execution matter in global health. They were present in strategic briefings before plenary sessions began and in media engagements long after the halls quieted. They connected multinational executives with regional stakeholders, translated policy nuance into actionable strategy, and ensured that complex science was communicated with clarity and credibility. What appears seamless to outside observers is the product of preparation, relationships and earned trust.
In conversations across the conference, one theme consistently surfaced. India is not simply participating in global health innovation. It is becoming a scale engine and a source of intellectual capital for it.
Moderating the panel titled “Next-Gen Biologics & Advanced Modalities: From Discovery to Clinical Proof & CMC at Scale” provided a vantage point across the ecosystem required to move science forward.
Mr. Stefan Miltenyi, Founder and President of Miltenyi Biotec, offered a global perspective on cellular technologies. Dr. Raches Ella of Bharat Biotech highlighted India’s innovation strength and vaccine leadership. Dr. Darrin Morrissey of NIBRT addressed bioprocessing excellence and talent development. Dr. Sai Praveen Haranath of Apollo HealthAxis provided the health system lens. Mr. V. Simpson E. of ImmunoACT contributed the CAR-T commercialization perspective. Dr. Jose Castillo of Quantoom Biosciences focused on scalable mRNA platforms. Dr. Madhuri Vusirikala of Actinium Pharmaceuticals shared expertise in radiopharmaceuticals and precision oncology.
The dialogue moved decisively beyond novelty and into operational reality.
First, next-generation biologics are no longer theoretical. Cell and gene therapies, mRNA platforms, and radiopharmaceuticals are demonstrating clinical proof. The inflection point lies in integrating discovery, regulatory rigor, and Chemistry, Manufacturing, and Controls into one coherent strategy. Science and systems cannot operate in parallel lanes.
Second, precision oncology is redefining risk and dignity. Radioligand and targeted therapies allow clinicians to treat tumors with increasing specificity while minimizing collateral damage. The future of cancer care is not only about survival. It is about enabling patients to live with fewer disruptions and greater humanity.
Third, CAR-T and other personalized therapies expose the access equation. Manufacturing variability, infrastructure constraints, and cost barriers mean that only a fraction of eligible patients receive these breakthroughs. For countries such as India, solving affordability and ecosystem readiness represents a global opportunity.
Fourth, India’s comparative advantage lies in scale and intellectual curiosity. Large vaccine programs, multi-site clinical trials that generate generalizable data, and cost-effective manufacturing create conditions few countries can replicate. When coupled with research partnerships and workforce training, advanced modalities can move beyond niche adoption.
Fifth, manufacturing is the make-or-break factor. Biologics and gene therapies are inherently variable systems. Standardizing processes, strengthening CMC capabilities, and building skilled talent pipelines will determine whether innovation remains confined to laboratories or reaches populations at meaningful scale.
Across each theme, the conversation shifted from breakthrough to delivery.
For FINN Partners, BIOAsia reflects how global health leadership is practiced across five continents, bridging multinational clients, emerging innovators, government leaders, and investors. Teams across India, Asia, Europe, and the United States engage daily in shaping reputations, aligning policies, and facilitating market entry for companies advancing human health.
SPAG FINN Partners’ participation in the FINN global network creates a strategic advantage. It enables global clients to navigate India’s industry and policy landscape with confidence while supporting Indian innovators in projecting their ambitions onto the world stage. It reflects a shared ethos grounded in preparation, relationships, and purpose.
At BIOAsia 2026, Hyderabad’s Global Capability Centers stood out as platforms for bioprocessing, digital health integration, and advanced analytics. Multinational leaders increasingly view India not merely as a market, but as a partner in innovation. Government officials emphasized regulatory evolution and infrastructure investment as catalysts for sustained growth.
Advanced biologics promise extraordinary outcomes. Delivering them at scale requires disciplined manufacturing, workforce training, regulatory harmonization, and industry confidence – trust built through transparency, collaboration, and purpose.
BIOAsia 2026 demonstrated that the center of gravity in global health innovation is expanding. India is asserting itself as a scale engine. Multinationals are recalibrating for partnership. Governments are investing in capability.
The conversation has shifted. The responsibility now is to deliver. Come to India!
POSTED BY: Gil Bashe
